Boston Scientific (BSX) Stock Price, News & Analysis

Boston Scientific logo
$105.01 +0.04 (+0.03%)
Closing price 02/6/2025 03:59 PM Eastern
Extended Trading
$104.62 -0.38 (-0.36%)
As of 02/6/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Boston Scientific Stock (NYSE:BSX)

Key Stats

Today's Range
$104.73
$105.90
50-Day Range
$88.03
$104.95
52-Week Range
$64.39
$107.17
Volume
6.38 million shs
Average Volume
6.29 million shs
Market Capitalization
$154.76 billion
P/E Ratio
86.78
Dividend Yield
N/A
Price Target
$104.26
Consensus Rating
Buy

Company Overview

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
95th Percentile Overall Score

BSX MarketRank™: 

Boston Scientific scored higher than 95% of companies evaluated by MarketBeat, and ranked 56th out of 955 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Boston Scientific has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 21 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Boston Scientific has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Boston Scientific's stock forecast and price target.
  • Earnings Growth

    Earnings for Boston Scientific are expected to grow by 12.60% in the coming year, from $2.46 to $2.77 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Boston Scientific is 86.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.34.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Boston Scientific is 86.78, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.37.

  • Price to Earnings Growth Ratio

    Boston Scientific has a PEG Ratio of 2.68. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Boston Scientific has a P/B Ratio of 7.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Boston Scientific's valuation and earnings.
  • Percentage of Shares Shorted

    0.98% of the outstanding shares of Boston Scientific have been sold short.
  • Short Interest Ratio / Days to Cover

    Boston Scientific has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Boston Scientific has recently decreased by 0.83%, indicating that investor sentiment is improving.
  • Dividend Yield

    Boston Scientific does not currently pay a dividend.

  • Dividend Growth

    Boston Scientific does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.98% of the outstanding shares of Boston Scientific have been sold short.
  • Short Interest Ratio / Days to Cover

    Boston Scientific has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Boston Scientific has recently decreased by 0.83%, indicating that investor sentiment is improving.
  • News Sentiment

    Boston Scientific has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 83 news articles for Boston Scientific this week, compared to 20 articles on an average week.
  • Search Interest

    57 people have searched for BSX on MarketBeat in the last 30 days. This is an increase of 104% compared to the previous 30 days.
  • MarketBeat Follows

    21 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is an increase of 91% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Boston Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,464,725.00 in company stock.

  • Percentage Held by Insiders

    Only 0.50% of the stock of Boston Scientific is held by insiders.

  • Percentage Held by Institutions

    89.07% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Boston Scientific's insider trading history.
Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

BSX Stock News Headlines

Needham Remains a Hold on Boston Scientific (BSX)
Better than Bitcoin – and potentially more profitable
The world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin Skimming allows you to “skim” cash into your account thanks to 2025’s surging Bitcoin market.
Boston Scientific (BSX) Gets a Buy from Barclays
Boston Scientific price target raised to $115 from $110 at BofA
See More Headlines

BSX Stock Analysis - Frequently Asked Questions

Boston Scientific's stock was trading at $89.32 on January 1st, 2025. Since then, BSX stock has increased by 17.6% and is now trading at $105.0060.
View the best growth stocks for 2025 here
.

Boston Scientific Co. (NYSE:BSX) posted its earnings results on Wednesday, February, 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.26% and a trailing twelve-month return on equity of 17.23%.
Read the conference call transcript
.

The following companies are subsidiaries of Boston Scientific: VertiFlex, BTG, Augmenix, Veniti, Claret Medical, Cryterion Medical, nVision Medical, and others.

Boston Scientific's top institutional shareholders include Bank of New York Mellon Corp (0.85%), Charles Schwab Investment Management Inc. (0.58%), Fisher Asset Management LLC (0.39%) and Vontobel Holding Ltd. (0.38%). Insiders that own company stock include Michael F Mahoney, Daniel J Brennan, Joseph Michael Fitzgerald, Jeffrey B Mirviss, Edward J Ludwig, Edward J Ludwig, John Bradley Sorenson, Jonathan Monson, Eric Francis Yves Thepaut, Wendy Carruthers, Vance R Brown, Nelda J Connors, Arthur C Butcher, Charles J Dockendorff, Ian T Meredith, David A Pierce and Scott Olson.
View institutional ownership trends
.

Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Boston Scientific investors own include BlackRock (BLK), Broadcom (AVGO), ServiceNow (NOW), UnitedHealth Group (UNH), The Goldman Sachs Group (GS), NVIDIA (NVDA) and Illinois Tool Works (ITW).

Company Calendar

Last Earnings
2/05/2025
Today
2/06/2025
Next Earnings (Estimated)
4/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
10113710
Employees
48,000
Year Founded
1979

Price Target and Rating

Average Stock Price Target
$104.26
High Stock Price Target
$122.00
Low Stock Price Target
$86.00
Potential Upside/Downside
-0.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
23 Analysts

Profitability

Net Income
$1.59 billion
Pretax Margin
13.84%

Debt

Sales & Book Value

Annual Sales
$15.91 billion
Cash Flow
$2.98 per share
Book Value
$13.33 per share

Miscellaneous

Outstanding Shares
1,473,827,000
Free Float
1,466,458,000
Market Cap
$154.76 billion
Optionable
Optionable
Beta
0.80

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NYSE:BSX) was last updated on 2/7/2025 by MarketBeat.com Staff
From Our Partners